智通财经APP获悉，中邮证券发布研报称，2025年初至今医药板块震荡上行，短暂回调后性价比凸显， 目前医药板块估值虽处于2010年以来历史中位，溢价率较高，但医药股市值占比仍有提升空间；而板块 业绩处于筑底阶段，随着板块集采、院内反腐等负面因素出清，2026年有望表现突出。 中邮证券主要观点如下： 创新药产业链：创新为纲，重视国产优质创新临床数据催化以及产业链盈利修复机会 创新药：国内资产全球认可度快速提升，MNC专利悬崖迫近，新品迭代需求强烈，美国药价政策频 出，利好国产新药出海，Top MNC对国内创新药资产关注度持续上升；国内则即将迎来医保商保协同 发力阶段，国产新药商业化前景优异；国内投融资表现较好，港股IPO热情高涨。赛道方面PD- (L)1/VEGF双抗赛道出海市场热度与交易价值持续攀升，且与ADC机制互补，协同增效或成热点；ADC 关注具备广谱适应症治疗潜力的"下一代"ADC以及联用治疗地位提升机遇；自免领域关注具备高成药把 握和协同疗效的双抗类资产以及口服大市场需求；siRNA具备高效低毒、疗效持久的优势，关注新靶点 的发现与肝外递送平台的发展。受益标的：信达生物、康方生物、科伦博泰生物、迈威 ...

万泰生物所属申万行业为：医药生物-生物制品-疫苗。所属概念板块包括：体外诊断、疫苗、医疗器 械、抗原检测、大盘等。 12月1日，万泰生物盘中上涨2.14%，截至10:35，报49.05元/股，成交1.06亿元，换手率0.17%，总市值 620.54亿元。 资金流向方面，主力资金净流出315.83万元，特大单买入141.04万元，占比1.33%，卖出423.72万元，占 比4.00%；大单买入2199.13万元，占比20.76%，卖出2232.28万元，占比21.07%。 万泰生物今年以来股价跌30.39%，近5个交易日跌4.76%，近20日跌11.21%，近60日跌16.35%。 资料显示，北京万泰生物药业股份有限公司位于北京市昌平区科学园路31号，成立日期1991年4月24 日，上市日期2020年4月29日，公司主营业务涉及体外诊断试剂、仪器与疫苗的研发、生产及销售。主 营业务收入构成为：诊断试剂67.06%，疫苗20.36%，诊断仪器4.98%，代理产品4.97%，其他(补 充)1.88%，活性原料0.76%。 责任编辑：小浪快报 截至9月30日，万泰生物股东户数4.20万，较上期增加9.41%；人均流通 ...

Core Insights - Kosen Technology's stock price increased by 2.05% on December 1, reaching 13.43 CNY per share, with a trading volume of 406 million CNY and a market capitalization of 7.452 billion CNY [1] Financial Performance - Kosen Technology's stock has risen 72.18% year-to-date, with a 15.98% increase over the last five trading days, a 0.90% increase over the last 20 days, and a 15.27% decline over the last 60 days [1] - For the period from January to September 2025, Kosen Technology reported revenue of 2.453 billion CNY, a year-on-year decrease of 6.45%, while the net profit attributable to shareholders was -115 million CNY, reflecting a year-on-year increase of 50.94% [2] Shareholder Information - As of September 30, Kosen Technology had 94,300 shareholders, an increase of 27.57% from the previous period, with an average of 5,884 circulating shares per shareholder, a decrease of 21.61% [2] Business Overview - Kosen Technology, established in December 2010 and listed in February 2017, specializes in precision manufacturing processes including die casting, forging, stamping, CNC, laser cutting, laser welding, MIM, and precision injection molding [2] - The company's revenue composition includes 76.75% from consumer electronics components, 10.58% from new energy-storage business, 8.10% from medical surgical instrument components, and 3.33% from other precision metal components [2] Dividend Information - Kosen Technology has distributed a total of 283 million CNY in dividends since its A-share listing, with cumulative distributions of 71.68 million CNY over the past three years [3]

医疗器械概念+人民币贬值受益+专精特新 来源：新浪证券-红岸工作室 11月28日，海泰新光跌1.96%，成交额5575.79万元，换手率1.04%，总市值53.39亿元。 异动分析 主力轻度控盘，筹码分布较为分散，主力成交额2038.97万，占总成交额的13.34%。 技术面：筹码平均交易成本为46.61元 该股筹码平均交易成本为46.61元，近期筹码减仓，但减仓程度减缓；目前股价靠近压力位45.45，谨防 压力位处回调，若突破压力位则可能会开启一波上涨行情。 1、公司始终致力于将光学技术与医疗器械行业的前沿应用趋势相结合，研究发展高性能的尖端内窥镜 器械产品。目前，公司是国内少有的具备从核心部件、关键设备到系统集成的行业垂直整合能力的企 业。 2、根据2024年年报，公司海外营收占比为69.12%，受益于人民币贬值。 3、专精特新"小巨人"企业是全国中小企业评定工作中最高等级、最具权威的荣誉称号，是指专注于细 分市场、创新能力强、市场占有率高、掌握关键核心技术、质量效益优的排头兵企业，对于提升中小企 业自身的竞争力，以及提升产业链、供应链稳定性和竞争力具有重大意义。公司已入选工信部专精特新 小巨人企业名单。 ...

Core Viewpoint - Wante Bio's stock has experienced a significant decline in 2023, with a year-to-date drop of 31.73% and a recent 60-day decline of 17.40% [2] Company Overview - Wante Bio, established on April 24, 1991, and listed on April 29, 2020, is located in Changping District, Beijing. The company specializes in the research, production, and sales of in vitro diagnostic reagents, instruments, and vaccines [2] - The revenue composition of Wante Bio includes: diagnostic reagents (67.06%), vaccines (20.36%), diagnostic instruments (4.98%), agency products (4.97%), other (1.88%), and active raw materials (0.76%) [2] - As of September 30, 2025, Wante Bio had 42,000 shareholders, an increase of 9.41% from the previous period, with an average of 30,124 circulating shares per shareholder, a decrease of 8.60% [2] Financial Performance - For the period from January to September 2025, Wante Bio reported a revenue of 1.498 billion yuan, a year-on-year decrease of 23.09%, and a net profit attributable to shareholders of -173 million yuan, a year-on-year decrease of 165.04% [2] - Since its A-share listing, Wante Bio has distributed a total of 1.541 billion yuan in dividends, with 1.311 billion yuan distributed over the past three years [3] Shareholder Structure - As of September 30, 2025, the top ten circulating shareholders of Wante Bio include Hong Kong Central Clearing Limited, which holds 12.8991 million shares (a decrease of 9.8553 million shares), and Huatai-PB CSI 300 ETF, holding 6.4061 million shares (a decrease of 318,300 shares) [3] - The China National Securities Bio-Medical Index A has entered the top ten circulating shareholders with 4.9609 million shares as a new shareholder, while E Fund CSI 300 Medical ETF has exited the list [3] Market Activity - On November 28, Wante Bio's stock price fell by 2.02%, trading at 48.10 yuan per share, with a total transaction volume of 131 million yuan and a turnover rate of 0.21%. The total market capitalization is 60.852 billion yuan [1] - In terms of capital flow, there was a net outflow of 17.3687 million yuan from main funds, with large orders showing a buy of 23.094 million yuan (17.66%) and a sell of 27.222 million yuan (20.82%) [1]

11月28日，华熙生物盘中下跌2.01%，截至09:54，报46.79元/股，成交5361.81万元，换手率0.24%，总 市值225.38亿元。 资金流向方面，主力资金净流出220.33万元，特大单买入216.98万元，占比4.05%，卖出397.92万元，占 比7.42%；大单买入943.10万元，占比17.59%，卖出982.50万元，占比18.32%。 华熙生物今年以来股价跌8.13%，近5个交易日跌4.26%，近20日跌13.34%，近60日跌19.02%。 资料显示，华熙生物科技股份有限公司位于山东省济南市高新技术开发区天辰大街678号，成立日期 2000年1月3日，上市日期2019年11月6日，公司主营业务涉及微生物发酵和交联两大技术平台,开发有助 于人类生命健康的生物活性材料,建立了从原料到医疗终端产品、功能性护肤品及功能性食品的全产业 链业务体系,服务于全球的医药、化妆品、食品制造企业、医疗机构及终端用户。主营业务收入构成 为：皮肤科学创新转化业务40.34%，医疗终端产品29.76%，原料产品27.70%，其他2.17%，其他(补 充)0.03%。 截至11月20日，华熙生物股东户数3.0 ...

Core Viewpoint - TaiLin Bio's stock price has shown volatility, with a year-to-date increase of 56.12%, but a recent decline over the past 20 and 60 days, indicating potential market fluctuations and investor sentiment changes [1]. Financial Performance - For the period from January to September 2025, TaiLin Bio reported revenue of 213 million yuan, a year-on-year decrease of 12.08%, while net profit attributable to shareholders was 14.72 million yuan, reflecting a year-on-year increase of 30.13% [2]. - Cumulative cash dividends since the company's A-share listing amount to 117 million yuan, with 60.1 million yuan distributed over the past three years [3]. Shareholder Information - As of September 30, 2025, the number of shareholders decreased by 13.61% to 9,437, while the average circulating shares per person increased by 15.76% to 8,058 shares [2]. - Notably, the fund "Noan Multi-Strategy Mixed A" has exited the list of the top ten circulating shareholders [3]. Market Activity - On November 28, TaiLin Bio's stock price fell by 2.02% to 26.65 yuan per share, with a trading volume of 19.08 million yuan and a turnover rate of 0.93%, resulting in a total market capitalization of 3.23 billion yuan [1]. - The net inflow of main funds was 1.1 million yuan, with large orders accounting for 15.25% of purchases and 9.49% of sales [1].

Core Viewpoint - The company, Hangya Technology, is positioned as a key player in the aviation engine and medical device sectors, benefiting from its specialized technology and international client base, while also experiencing impacts from currency fluctuations. Group 1: Company Overview - Hangya Technology is a domestic enterprise capable of mass-producing compressor blades using precision forging technology, supplying major international engine manufacturers [2] - The company has established a manufacturing system for medical orthopedic joint forgings and is gradually entering the finished product processing field for orthopedic joints [4] - As of September 30, the company reported a revenue of 530 million yuan, a year-on-year increase of 1.95%, and a net profit of 77.87 million yuan, a year-on-year decrease of 16.04% [9] Group 2: Market Position and Clientele - The company serves major global engine manufacturers, including Safran, Rolls-Royce, and GE Aviation, and is involved in the development and processing of components for advanced domestic engines [2] - Hangya Technology's products cover mainstream engine models such as Safran LEAP, CFM 56, and GE Aviation's CF34, with applications in Boeing and Airbus aircraft [2] Group 3: Recognition and Financials - The company has been recognized as a "specialized, refined, distinctive, and innovative" small giant enterprise, indicating its strong market position and innovation capabilities [3] - The overseas revenue accounted for 53.54% of total revenue, benefiting from the depreciation of the yuan [4] Group 4: Stock Performance and Technical Analysis - On November 27, the stock price of Hangya Technology fell by 0.97%, with a trading volume of 78.77 million yuan and a market capitalization of 5.808 billion yuan [1] - The average trading cost of the stock is 24.59 yuan, with the current price approaching a resistance level of 22.60 yuan, indicating potential for upward movement if the resistance is broken [7]

来源：新浪证券-红岸工作室 11月27日，春立医疗跌0.69%，成交额3070.31万元，换手率0.43%，总市值93.36亿元。 异动分析 牙科医疗+医疗器械概念+智能医疗+专精特新+京津冀一体化 1、国内领先的骨科医疗器械厂商，春立医疗主营业务系植入性骨科医疗器械的研发、生产与销售，包 括口腔金属和隐形正畸 口腔种植和修复。 公司拟设计多孔钽定制个体化牙种植体产品并完成生产转 换， 目前处于设计送检阶段。 2、公司是国内领先的骨科医疗器械厂商，主营业务系植入性骨科医疗器械的研发、生产与销售。公司 主要产品为关节假体产品及脊柱类植入产品，其中关节假体产品涵盖髋、膝、肩、肘四大人体关节，脊 柱类植入产品为脊柱内固定系统的全系列产品组合。 3、2024年10月9日互动易：我公司是一家专注于骨科医疗器械领域的高新技术企业，产品涵盖关节类、 脊柱类、运动医学类、创伤类等全系列骨科产品。同时公司已经取得了髋关节手术机器人、膝关节手术 机器人等产品的注册证，以及手术规划的"医学图像处理软件"。这些产品和软件的开发表明公司在智能 医疗等领域进行的布局和研发投入。 4、专精特新"小巨人"企业是全国中小企业评定工作中最高等级 ...

Core Viewpoint - Fu Yuan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 61.36% and a recent uptick in trading activity, indicating strong market interest and potential investment opportunities [1][2]. Company Overview - Fu Yuan Pharmaceutical, established on February 3, 1999, and listed on June 30, 2022, is located in Tongzhou District, Beijing. The company specializes in the research, production, and sales of pharmaceutical preparations and medical devices, with 94.09% of its revenue coming from pharmaceutical preparations and 6.00% from medical devices [1][2]. Financial Performance - For the period from January to September 2025, Fu Yuan Pharmaceutical reported a revenue of 2.52 billion yuan, a year-on-year decrease of 1.04%, and a net profit attributable to shareholders of 375 million yuan, down 6.39% compared to the previous year [2][3]. - The company has distributed a total of 661 million yuan in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, the number of shareholders for Fu Yuan Pharmaceutical was 22,700, a decrease of 3.39% from the previous period. The average number of circulating shares per shareholder increased by 3.51% to 21,153 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 4.25 million shares, a reduction of 1.25 million shares from the previous period. New entrants include E Fund Healthcare Industry Mixed A and Ping An New Xin Pioneer Mixed A, holding 2.56 million and 2.12 million shares, respectively [3]. Market Activity - On November 27, Fu Yuan Pharmaceutical's stock price rose by 2.04% to 25.03 yuan per share, with a trading volume of 384 million yuan and a turnover rate of 3.25%, resulting in a total market capitalization of 12.01 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" four times this year, with the most recent occurrence on September 5, where it recorded a net buy of -42.23 million yuan [1].